Edesa Biotechの将来のP / E
Edesa Biotechの将来のP / Eは何ですか。
Edesa Biotech, Inc.の将来のP / Eは0.17です。
将来のP / Eの定義は何ですか。
未来比率P / E (株価収益率)は、企業の株価と今後12ヶ月間の1株当たり利益見込額との比率です。
The forward price to earnings ratio is similar to trailing price to earnings ratio but instead of net income uses estimated net earnings over next 12 months. Estimates are typically derived as the mean of those published by a select group of analysts with selection criteria varying. The forward price-to-earnings ratio is a powerful, but limited tool. It allows a quick snapshot of the company’s finances without getting down in the details of an accounting report.
NASDAQのセクタHealth Careにおける将来のP / Eの企業と比べるEdesa Biotech
Edesa Biotechは何をしますか。
Edesa Biotech, Inc., a biopharmaceutical company, engages in acquiring, developing, and commercializing clinical-stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical treatment that is in Phase 2B clinical study for chronic allergic contact dermatitis. It has a license agreement with NovImmune SA to develop monoclonal antibodies targeting TLR4 and CXCL10. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada.
Edesa Biotechと類似の将来のp / e
- Lekoilの将来のP / Eは0.14です。
- Mediclinic International plcの将来のP / Eは0.14です。
- Sintex Industriesの将来のP / Eは0.15です。
- Dewan Housing Financeの将来のP / Eは0.15です。
- Young & Co.'s Brewery Plcの将来のP / Eは0.17です。
- Sumeet Industriesの将来のP / Eは0.17です。
- Edesa Biotechの将来のP / Eは0.17です。
- Nichols Plcの将来のP / Eは0.17です。
- Vertex Incの将来のP / Eは0.18です。
- Quantum Genomics SAの将来のP / Eは0.18です。
- Dewan Housing Financeの将来のP / Eは0.18です。
- Churchill China Plcの将来のP / Eは0.18です。
- Kwalityの将来のP / Eは0.19です。